Boswellia Supplements: The AKBA Number That Isn't on the Label
Educational overview — not medical advice. Boswellia is an adjunct for symptom relief, not a cure for osteoarthritis or a way to regrow cartilage — if you have significant joint pain, see a clinician. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Boswellia's potent active is AKBA (acetyl-11-keto-β-boswellic acid) — a 5-LOX inhibitor, not the total extract weight or the generic "65% boswellic acids" spec. The genuinely encouraging part: AKBA-standardized-extract trials cut knee-osteoarthritis pain relatively fast, with onset around 5–7 days (Sengupta 2008; Vishal 2011), and a meta-analysis of 7 RCTs found benefit in a consistent direction (Yu 2020, high heterogeneity). The catch that defines this category: almost no product discloses its AKBA — of 13 we track, only 4 print an AKBA % or a branded clinical extract.
As an Amazon Associate we earn from qualifying purchases. Ranked by AKBA/standardization disclosure, never commissions.
Start here
What boswellia is (and what actually does the work)
Boswellia serrata (Indian frankincense) is marketed for "joint comfort," and that part is grounded — but the ingredient responsible is a specific boswellic acid, AKBA (acetyl-11-keto-β-boswellic acid). AKBA is the most potent natural inhibitor of 5-lipoxygenase (5-LOX), an enzyme in the leukotriene arm of the inflammatory cascade (Safayhi 1996), and structure-activity work confirms the AKBA structure — not the total boswellic-acid content — is what drives that 5-LOX inhibition (Sailer 1996). What does not reliably do the work: the total extract weight, or a plain "65% boswellic acids" figure, because that number lumps in far less active acids and says nothing about AKBA. That single fact — the active is AKBA, not "boswellic acids" in general — is why the milligram or percentage on most labels is close to meaningless.
Does it work? (the short version)
For knee-osteoarthritis symptoms, and only from AKBA-standardized extracts, the evidence is relatively encouraging and unusually fast. A randomized trial of 5-Loxin (30% AKBA) reported improvement with onset by day 7 and a drop in the cartilage-degrading enzyme marker MMP-3 (Sengupta 2008); a trial of Aflapin (20% AKBA) reported a large reduction in pain on the VAS scale with onset by day 5 (Vishal 2011); and a head-to-head trial found Aflapin outperformed 5-Loxin (Sengupta 2010). A 2020 meta-analysis of 7 RCTs found benefit in a consistent direction, but with high heterogeneity, so treat the pooled size cautiously (Yu 2020). Be honest about scope: this is symptom relief, not cure — MMP-3 dropping means degradation may be slowed, not that cartilage is rebuilt.
The one-line takeaway The evidence is for an AKBA-standardized extract you mostly can't identify from the bottle. Of the 13 products we track, only 4 disclose an AKBA % or a branded clinical extract and 9 leave it a black box — so shop on AKBA disclosure first, not on the "65% boswellic acids" or milligram number.
The buying problem: AKBA, not "65% boswellic acids"
Two traps. First, the label: "1200 mg boswellia," "65% boswellic acids," and a bare extract weight all describe total extract or total-acid content, not the AKBA that was studied (AKBA vs boswellic acids). Second, the comparison: because AKBA is almost never disclosed, a trial-grade ranking is possible only for the 4 products that name an AKBA % or a clinical extract (best boswellia by disclosure). The honest move is to prioritize any product that actually discloses AKBA — those are the only ones you can match to the clinical evidence.
Frequently asked questions
What is the active ingredient in boswellia?
AKBA (acetyl-11-keto-β-boswellic acid), a 5-LOX inhibitor (Safayhi 1996; Sailer 1996) — not the total extract weight or the generic "65% boswellic acids" spec. That's why the front-of-bottle number doesn't tell you the dose that matters.
Does boswellia actually work for joint pain?
For knee-OA symptoms, the AKBA-standardized-extract RCTs are encouraging and fast (day-5 to day-7 onset; Sengupta 2008, Vishal 2011), and a meta of 7 RCTs was consistent in direction (Yu 2020, high heterogeneity). It's an adjunct for symptom relief, not a cure.
How much should I take?
Roughly 100–250 mg/day of an AKBA-standardized extract (5-Loxin was studied at 100–250 mg; Aflapin at 100 mg). Whether the extract discloses AKBA matters more than the raw milligram total.
Why is comparing products so hard?
The number that matters — the AKBA fraction — is almost never printed, and commercial AKBA ranges from 3.83% down to 0.03% (Beghelli 2017). Only 4 of 13 products we track disclose an AKBA % or branded extract.
Related guides
- Boswellia for osteoarthritis — the honest, fast-onset evidence and adjunct-not-cure framing
- AKBA vs boswellic acids — why the "65%" number isn't the active
- Boswellia dosage guide — 100–250 mg AKBA-standardized extract + a disclosure checker
Sources
- Sengupta K, et al. "A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee." Arthritis Res Ther. 2008. PMID: 18667054
- Vishal AA, et al. "A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin in subjects with osteoarthritis of knee." Int J Med Sci. 2011. PMID: 22022214
- Yu G, et al. "Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis." BMC Complement Med Ther. 2020. PMID: 32680575
- Full product dataset: /boswellia/cost-by-brand.json (CC BY 4.0).